Asunto(s)
Antiinfecciosos/efectos adversos , Anticoagulantes/efectos adversos , Hemorragia Gastrointestinal/inducido químicamente , Ácido Nalidíxico/efectos adversos , Hemorragia Posoperatoria/inducido químicamente , Warfarina/efectos adversos , Anciano , Antiinfecciosos/uso terapéutico , Anticoagulantes/uso terapéutico , Interacciones Farmacológicas , Hemorragia Gastrointestinal/diagnóstico , Humanos , Isquemia/cirugía , Pierna/irrigación sanguínea , Pierna/cirugía , Masculino , Ácido Nalidíxico/uso terapéutico , Hemorragia Posoperatoria/diagnóstico , Tromboembolia/prevención & control , Uretritis/complicaciones , Uretritis/tratamiento farmacológico , Warfarina/uso terapéuticoAsunto(s)
Hipertensión/epidemiología , Medicina del Trabajo , Adolescente , Adulto , Anciano , Femenino , Humanos , Masculino , Persona de Mediana Edad , RiesgoRESUMEN
The intravenous form of the Soviet anti-arrhythmic pharmaceutical ethacizine has been studied clinically. The pharmaceutical was administered to 30 patients with ventricular rhythm disorders during 3 to 15 minutes, at an average dose of 0.63 mg per 1 kg body weight, under the Holter monitor control. On the average the effect became apparent 6.5 min, after the injection and lasted on the average 149 +/- 15 min. Etacizine was effective in 77% of cases. It was established that there was no pronounced negative effect on the heart rate and the arterial pressure. Uzineg the tetrapolar rheography method it was shown that there was no pronounced negative effect on the central hemodynamics. The observation was made that etacizine induced a moderate decrease of the conductivity in atria AV-system and ventricles. Etacisin could be successfully used for rapid suppression of the ventricle rhythm disorders in various forms of coronary disease of the heart.
Asunto(s)
Antiarrítmicos/uso terapéutico , Complejos Cardíacos Prematuros/tratamiento farmacológico , Moricizina/análogos & derivados , Fenotiazinas/uso terapéutico , Taquicardia Paroxística/tratamiento farmacológico , Adulto , Anciano , Complejos Cardíacos Prematuros/fisiopatología , Femenino , Ventrículos Cardíacos/fisiopatología , Hemodinámica/efectos de los fármacos , Humanos , Masculino , Persona de Mediana Edad , Taquicardia Paroxística/fisiopatologíaAsunto(s)
Hipoxia/prevención & control , Inosina Difosfato/uso terapéutico , Nucleótidos de Inosina/uso terapéutico , Adulto , Anciano , Femenino , Insuficiencia Cardíaca/metabolismo , Humanos , Masculino , Persona de Mediana Edad , Fosforilación Oxidativa/efectos de los fármacos , Consumo de Oxígeno/efectos de los fármacos , Oxihemoglobinas/metabolismoAsunto(s)
Tejido Adiposo/enzimología , Enfermedad Coronaria/dietoterapia , Dieta Reductora , Fosfolipasas A/metabolismo , Fosfolipasas/metabolismo , Adulto , Enfermedad Coronaria/complicaciones , Enfermedad Coronaria/enzimología , Humanos , Lípidos/sangre , Lipoproteínas/sangre , Masculino , Persona de Mediana Edad , Obesidad/complicaciones , Fosfolipasas A/sangreAsunto(s)
Dopamina/uso terapéutico , Glucagón/uso terapéutico , Insuficiencia Cardíaca/tratamiento farmacológico , Isoproterenol/uso terapéutico , Adulto , Anciano , Presión Sanguínea , Gasto Cardíaco , Femenino , Frecuencia Cardíaca , Humanos , Masculino , Persona de Mediana Edad , Contracción Miocárdica , Volumen SistólicoRESUMEN
It has been shown with special reference to 35 patients suffering from myocardial infarction, atherosclerotic cardiosclerosis and rheumatic heart diseases associated with varying degrees of circulatory insufficiency that the final amount of distribution and halflife of lidocaine directly correlated with the cardiac index. A formula has been suggested for calculating the amount of distribution of the drug on the basis of the cardiac index. It has been demonstrated that the formula can be used for the development of therapeutically effective lidocaine concentration in the patients' blood.
Asunto(s)
Insuficiencia Cardíaca/sangre , Lidocaína/sangre , Enfermedad Coronaria/sangre , Enfermedad Coronaria/tratamiento farmacológico , Insuficiencia Cardíaca/tratamiento farmacológico , Humanos , Cinética , Lidocaína/administración & dosificación , Matemática , Infarto del Miocardio/sangre , Infarto del Miocardio/tratamiento farmacológico , Cardiopatía Reumática/sangre , Cardiopatía Reumática/tratamiento farmacológico , Factores de TiempoRESUMEN
The pharmacodynamics and pharmacotherapy of phosphaden (adenosine-5-monophosphate), a Soviet activator of energy metabolism, were studied in patients with chronic ischemic heart disease. Functional and biochemical methods were used. It was established that phosphaden is an effective drug in the treatment of chronic ischemic heart disease. The results of clinical, functional and biochemical examination support this conclusion.